CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
ChAdOx1 biEBOVbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05079750
NCT05079750Phase 1Completed
CompareCT.gov

A Phase I Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in UK Healthy Adult Volunteers

University of Oxford·interventional·Posted Oct 15, 2021·Updated Apr 4, 2025

In Brief

A Phase 1 clinical trial evaluating ChAdOx1 biEBOV for Ebola. Completed, enrolled 26 participants across 1 site.

Detailed Summary

An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species in healthy adult volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedOct 15, 2021
Enrollment StartNov 11, 2021
Primary CompletionMar 21, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.7 years ago

Interventions

ChAdOx1 biEBOVbiological

ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)